New research suggests that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end traditional diet and exercise programs.
Research printed in a leading medical journal points out that while overweight individuals often shed about a fifth of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month after stopping.
"Individuals buying such medications should be cognizant of the danger of fast weight regain when the medication concludes," warns expert Dr. Susan Jebb.
This pace of recovery implies a reversion to starting weight in about a year and a half.
Comparing Treatments
The analysis, which examined 37 of studies involving thousands of patients, compared the results of these new drugs with older methods.
Researchers point out that people who shed pounds through diet and exercise typically have a less rapid weight regain—approximately 100 grams monthly—once they finish.
Understanding the Fast Regain
Nutrition scientists suggest the way of the jabs accounts for the heightened weight return.
These medications imitate a natural hormone called GLP-1, which controls appetite.
"Sustained high doses of the hormone levels far above than the body's typical production might result in the system to produce less of its endogenous hormone, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' means hunger is uncontrolled, making binge eating far more likely."
An Ongoing Issue?
Health authorities suggest the jabs for people with weight-linked health risks, alongside prescribed lifestyle changes.
Many experts contend that, considering the high risk of weight regain, the therapy is often life-long.
This opinion is reinforced by pharmaceutical companies, who say that the results "emphasize the chronic character of obesity," akin to managing diseases like diabetes.
Patient Testimonies
Users who have stopped the jabs report a sudden resurgence of appetite.
"It was like a trigger that goes on and I was suddenly ravenous," said a patient.
This challenge is compounded if patients have not established permanent lifestyle or habit modifications during therapy.
Widespread Use
Recent estimates indicate that a significant number of people in the UK have used these injections in the past year, with demand continuing to grow.
- Use is more common among women than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the drugs through private prescriptions rather than the NHS.
Finally, clinicians emphasize that while these medications are powerful tools for shedding pounds, they are not a permanent fix and long-term success likely depends on ongoing behavioural changes.
